Journal of Dali University ›› 2023, Vol. 8 ›› Issue (4): 13-21.

Previous Articles     Next Articles

Investigation on the Mechanism of Lemai Granules in the Treatment of Vascular Dementia Based on Network Pharmacology and Molecular Docking

Wang JinyuZhou LonglongWang XuechangLi XiaodongGeng ShuqiongXia Conglong   

  1. 1.College of PharmacyDali UniversityDaliYunnan 671000China2.Department of PharmacyAnning First People's HospitalKunming 650300China

  • Received:2022-11-11 Revised:2022-12-22 Online:2023-04-15 Published:2023-04-25

Abstract:

ObjectiveTo investigate the mechanism of Lemai Granules in the treatment of vascular dementiaVDusing network pharmacology and molecular docking. MethodsThe active ingredients and targets of Lemai Granules were screened from the TCMSP databaseand the relevant targets of VD were obtained from GeneCardOMIMDrugBank and other databases. The intersection targets were obtained after merging and deduplication. Cytoscape 3.9.0 software was used for visual analysis of the "drug-active ingredient-target" network and protein-protein interaction network to obtain core active ingredients and targets. R 4.2.1 software was used for GO analysis and KEGG pathway enrichment analysis of intersection targetsand AutoDock Vina 1.5.6 software was used for molecular docking. ResultsQuercetinluteolinand kaempferol may be the core active ingredients for the treatment of VD by Lemai Granulesand core targets included AKT1PTGS2and TNF. GO analysis was mainly related to peptide response and cellular responses to chemical stress. KEGG mainly involved lipid and atherosclerosisPI3K-Akt signaling pathwayand other pathways. The molecular docking results showed that the binding activity between core active ingredients and core targets was strong. ConclusionLemai Granules can exert their therapeutic effects on VD through multiple targets and pathwaysmainly involving the suppression of inflammatory reaction and the regulation of neuronal apoptosis.

Key words:

"> font-size:10.5pt, ">Lemai Granules, vascular dementia, network pharmacology, molecular docking, mechanism of action

CLC Number: